Table 3 Qualitative summary of efficacy outcomes
A. SCS vs. active comparator studies | ||||
|---|---|---|---|---|
Trial Name/author | Outcome | Within group difference SCS | Within group difference Control | Between group difference SCS vs. control |
ESBY 1998 (vs CABG) | Nitrate drug usage | 6-mo + | 6-mo + | 6-mo = |
| Â | Â | 2-yr + | 2-yr + | 2-yr = |
| Â | Exercise capacity | 6-mo = | 6-mo + | 6-mo -- |
| Â | Total mortality | NR | NR | 6-mo + |
| Â | Â | NR | NR | 2-yr = |
| Â | Â | NR | NR | 5-yr = |
| Â | Non fatal morbidity | NR | NR | 6-mo = |
| Â | Ischemic burden | 6-mo = | 6-mo = | 6-mo = |
| Â | HRQoL (QLQ-AP & NHP) | 6-mo + | 6-mo + | 6-mo = |
| Â | Â | 2-yr + | 2-yr + | 2-yr = |
| Â | Â | 6-mo + | 6-mo+ | 6-mo = |
| Â | Angina | Â | Â | Â |
SpiRiT 2006* (vs PMR) | Exercise capacity | 3-mo + | 3-mo = | 3-mo = |
| Â | Â | 12-mo = | 12-mo = | 12-mo = |
| Â | CCS class | 3-mo + | 3-mo + | 3-mo + |
| Â | Â | 12-mo + | 12-mo + | 12-mo = |
| Â | HRQoL (SF-36 & | 3-mo + | 3-mo + | 3-mo = |
| Â | SAQ)* | 12-mo + | 12-mo + | 12-mo = |
B. SCS vs no SCS/SCS OFF studies | ||||
Trial Name/author | Outcome | Within group difference SCS | Within group difference Control | Between group difference SCS vs. control |
DeJongste 1994 | Exercise capacity | + | = | + |
| Â | Nitrate drug usage | + | = | + |
| Â | HRQoL (ADL score) | + | = | + |
Hautvast 1998 | Exercise capacity | + | = | + |
| Â | Nitrate drug usage | + | = | = |
| Â | HRQoL (LASA) | + | = | = |
| Â | Ischemic burden | + | = | = |
Jessurun 1999 | Exercise capacity | NR | NR | = |
| Â | Ischemic burden | NR | NR | = |
| Â | Nitrate drug usage | NR | NR | = |
DiPede 2001 Eddicks 2007 | Ischemic burden | NR | NR | = |
| Â | Exercise capacity | NR | NR | + |
| Â | Nitrate drug usage | NR | NR | + |
| Â | HRQoL (SAQ) | NR | NR | +/= |
| Â | (EQ-5D) | NR | NR | + |
| Â | CCS class | NR | NR | + |
| Â | Angina attacks | NR | NR | + |